TR
Trevi Therapeutics, Inc.
TRVI · NASDAQ
$14.89 -0.67% (-$0.10)
1M -17.64%
Market Cap $2.11B
P/E Ratio -
Div. Yield -
ROE 23.59%
Bulios Fair Price
$10.55
29.1% downside
Current Price
$14.89
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TRVI is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
18 /100
Expensive P/B 6.58x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 19.47%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
FCF margin N/A
Quality
0 /100
Poor ROIC 18.46%
ROE 23.59%
Asset turnover 0.00x
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 37.28x
Int. coverage N/A
Stability
43 /100
Moderate Beta 1.05x
EPS volatility 57.17%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TRVI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jennifer L. Good
Employees
34
Headquarters
New Haven
Upcoming events
12 NOV
Earnings
Upcoming earnings report